These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

476 related articles for article (PubMed ID: 29203661)

  • 1. Unusual zinc-binding mode of HDAC6-selective hydroxamate inhibitors.
    Porter NJ; Mahendran A; Breslow R; Christianson DW
    Proc Natl Acad Sci U S A; 2017 Dec; 114(51):13459-13464. PubMed ID: 29203661
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Methods for the expression, purification, and crystallization of histone deacetylase 6-inhibitor complexes.
    Osko JD; Christianson DW
    Methods Enzymol; 2019; 626():447-474. PubMed ID: 31606087
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Histone Deacetylase 6-Selective Inhibitors and the Influence of Capping Groups on Hydroxamate-Zinc Denticity.
    Porter NJ; Osko JD; Diedrich D; Kurz T; Hooker JM; Hansen FK; Christianson DW
    J Med Chem; 2018 Sep; 61(17):8054-8060. PubMed ID: 30118224
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Binding of inhibitors to active-site mutants of CD1, the enigmatic catalytic domain of histone deacetylase 6.
    Osko JD; Christianson DW
    Acta Crystallogr F Struct Biol Commun; 2020 Sep; 76(Pt 9):428-437. PubMed ID: 32880591
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Entropy as a Driver of Selectivity for Inhibitor Binding to Histone Deacetylase 6.
    Porter NJ; Wagner FF; Christianson DW
    Biochemistry; 2018 Jul; 57(26):3916-3924. PubMed ID: 29775292
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structural insights into HDAC6 tubulin deacetylation and its selective inhibition.
    Miyake Y; Keusch JJ; Wang L; Saito M; Hess D; Wang X; Melancon BJ; Helquist P; Gut H; Matthias P
    Nat Chem Biol; 2016 Sep; 12(9):748-54. PubMed ID: 27454931
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Investigation of non-hydroxamate scaffolds against HDAC6 inhibition: A pharmacophore modeling, molecular docking, and molecular dynamics simulation approach.
    Zeb A; Park C; Son M; Rampogu S; Alam SI; Park SJ; Lee KW
    J Bioinform Comput Biol; 2018 Jun; 16(3):1840015. PubMed ID: 29945500
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent advances in the discovery of potent and selective HDAC6 inhibitors.
    Wang XX; Wan RZ; Liu ZP
    Eur J Med Chem; 2018 Jan; 143():1406-1418. PubMed ID: 29133060
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of a New Isoxazole-3-hydroxamate-Based Histone Deacetylase 6 Inhibitor SS-208 with Antitumor Activity in Syngeneic Melanoma Mouse Models.
    Shen S; Hadley M; Ustinova K; Pavlicek J; Knox T; Noonepalle S; Tavares MT; Zimprich CA; Zhang G; Robers MB; Bařinka C; Kozikowski AP; Villagra A
    J Med Chem; 2019 Sep; 62(18):8557-8577. PubMed ID: 31414801
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemical Versatility in Catalysis and Inhibition of the Class IIb Histone Deacetylases.
    Christianson DW
    Acc Chem Res; 2024 Apr; 57(8):1135-1148. PubMed ID: 38530703
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structure-activity relationship study of thiazolyl-hydroxamate derivatives as selective histone deacetylase 6 inhibitors.
    Nam G; Jung JM; Park HJ; Baek SY; Baek KS; Mok HY; Kim DE; Jung YH
    Bioorg Med Chem; 2019 Aug; 27(15):3408-3420. PubMed ID: 31235266
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structural determinants of affinity and selectivity in the binding of inhibitors to histone deacetylase 6.
    Osko JD; Christianson DW
    Bioorg Med Chem Lett; 2020 Apr; 30(8):127023. PubMed ID: 32067866
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis and Biological Investigation of Oxazole Hydroxamates as Highly Selective Histone Deacetylase 6 (HDAC6) Inhibitors.
    Senger J; Melesina J; Marek M; Romier C; Oehme I; Witt O; Sippl W; Jung M
    J Med Chem; 2016 Feb; 59(4):1545-55. PubMed ID: 26653328
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and Biological Investigation of Phenothiazine-Based Benzhydroxamic Acids as Selective Histone Deacetylase 6 Inhibitors.
    Vögerl K; Ong N; Senger J; Herp D; Schmidtkunz K; Marek M; Müller M; Bartel K; Shaik TB; Porter NJ; Robaa D; Christianson DW; Romier C; Sippl W; Jung M; Bracher F
    J Med Chem; 2019 Feb; 62(3):1138-1166. PubMed ID: 30645113
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of Novel Histone Deacetylase 6-Selective Inhibitors Bearing 3,3,3-Trifluorolactic Amide (TFLAM) Motif as a Zinc Binding Group.
    Kurohara T; Tanaka K; Takahashi D; Ueda S; Yamashita Y; Takada Y; Takeshima H; Yu S; Itoh Y; Hase K; Suzuki T
    Chembiochem; 2021 Nov; 22(22):3158-3163. PubMed ID: 34224197
    [TBL] [Abstract][Full Text] [Related]  

  • 16. How Does Chirality Determine the Selective Inhibition of Histone Deacetylase 6? A Lesson from Trichostatin A Enantiomers Based on Molecular Dynamics.
    Zhang Y; Ying JB; Hong JJ; Li FC; Fu TT; Yang FY; Zheng GX; Yao XJ; Lou Y; Qiu Y; Xue WW; Zhu F
    ACS Chem Neurosci; 2019 May; 10(5):2467-2480. PubMed ID: 30784262
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Unique Molecular Interaction with the Histone Deacetylase 6 Catalytic Tunnel: Crystallographic and Biological Characterization of a Model Chemotype.
    Olaoye OO; Watson PR; Nawar N; Geletu M; Sedighi A; Bukhari S; Raouf YS; Manaswiyoungkul P; Erdogan F; Abdeldayem A; Cabral AD; Hassan MM; Toutah K; Shouksmith AE; Gawel JM; Israelian J; Radu TB; Kachhiyapatel N; de Araujo ED; Christianson DW; Gunning PT
    J Med Chem; 2021 Mar; 64(5):2691-2704. PubMed ID: 33576627
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PTG-0861: A novel HDAC6-selective inhibitor as a therapeutic strategy in acute myeloid leukaemia.
    Gawel JM; Shouksmith AE; Raouf YS; Nawar N; Toutah K; Bukhari S; Manaswiyoungkul P; Olaoye OO; Israelian J; Radu TB; Cabral AD; Sina D; Sedighi A; de Araujo ED; Gunning PT
    Eur J Med Chem; 2020 Sep; 201():112411. PubMed ID: 32615502
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structure-based design generated novel hydroxamic acid based preferential HDAC6 lead inhibitor with on-target cytotoxic activity against primary choroid plexus carcinoma.
    Kassab SE; Mowafy S; Alserw AM; Seliem JA; El-Naggar SM; Omar NN; Awad MM
    J Enzyme Inhib Med Chem; 2019 Dec; 34(1):1062-1077. PubMed ID: 31072216
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exploring Structural Determinants of Inhibitor Affinity and Selectivity in Complexes with Histone Deacetylase 6.
    Osko JD; Porter NJ; Narayana Reddy PA; Xiao YC; Rokka J; Jung M; Hooker JM; Salvino JM; Christianson DW
    J Med Chem; 2020 Jan; 63(1):295-308. PubMed ID: 31793776
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.